SuperworthBeOne Medicines market cap ONC
Share price times shares outstanding: what the whole company sells for, since 2016.
- Today, Oct 23, 2026
- $42.9B
- Highest close in our data
- $42.9B
- Oct 2026
BeOne Medicines is worth $42.9B at the close on Oct 23, 2026, at $377.63 a share.
That is up 26% over the last year and up 29% over five years.
Its highest close in our data was $42.9B in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $42.9B | $29.4B | $42.9B | +24% |
| 2025 | $34.6B | $18.8B | $40.5B | +78% |
| 2024 | $19.4B | $13.5B | $26.1B | +3% |
| 2023 | $18.9B | $17.5B | $28.1B | −17% |
| 2022 | $22.8B | $13.6B | $23.6B | −10% |
| 2021 | $25.4B | $23.3B | $37.6B | +8% |
| 2020 | $23.5B | $9.2B | $28.7B | +132% |
| 2019 | $10.1B | $7B | $12.6B | +25% |
| 2018 | $8.1B | $4.5B | $11.7B | +83% |
| 2017 | $4.4B | $1B | $4.6B | +343% |
| 2016 | $1B | $862.8M | $1.1B | n/a |
Against its peers
Companies in Biotechnology nearest BeOne Medicines' size, closest first, today.
| Company | Market cap |
|---|---|
| ONCBeOne Medicines | $42.9B |
| ALNYAlnylam Pharmaceuticals | $30B |
| UTHRUnited Therapeutics | $25.2B |
| INCYIncyte | $23.5B |
| REGNRegeneron Pharmaceuticals | $82.9B |
| EXELExelixis | $16B |
| NBIXNeurocrine Biosciences | $14.5B |
| HALOHalozyme Therapeutics | $14.3B |
| VRTXVertex Pharmaceuticals | $132.8B |
| TECHBIO-TECHNE | $11.4B |
| RGENRepligen | $10B |
| Peer median | $19.7B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on BeOne Medicines
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.